Table 2.
Treatment and clinical outcomes of severe and non-severe diabetic patients with COVID-19.
|
Total (n = 52) |
Severe (n = 21) |
Non-severe (n = 31) | p-value | |
|---|---|---|---|---|
| Treatment | ||||
| Oxygen therapy, n (%) | 23 (44.2) | 13 (61.9) | 10 (32.3) | 0.002 |
| Non-invasive | 8 (15.4) | 8 (38.1) | 0 | <0.001 |
| Invasive | 5 (9.6) | 5 (23.8) | 0 | <0.001 |
| ECMO | 0 | 0 | 0 | |
| Admission to ICU, n (%) | 12 (23.1) | 12 (57.1) | 0 | <0.001 |
| DM therapy, n (%) | ||||
| Insulin | 24 (46.2) | 7 (33.3) | 17 (54.8) | 0.159 |
| α-GI | 24 (46.2) | 5 (23.8) | 19 (61.3) | 0.021 |
| Metformin | 15 (28.8) | 5 (23.8) | 10 (32.3) | 0.754 |
| DPP4 inhibitor | 4 (7.7) | 1 (4.8) | 3 (9.77) | 1.000 |
| Thiazolidinedione | 2 (3.8) | 2 (9.5) | 0 | 0.149 |
| Sulfonylurea secretagogue | 2 (3.8) | 0 | 2 (6.5) | 0.514 |
| Non-sulfonylurea secretagogue | 2 (3.8) | 1 (4.8) | 1 (3.2) | 1.000 |
| Complications, n (%) | 15 (28.8) | |||
| ARDS | 11 (21.2) | 9 (42.9) | 2 (6.5) | 0.002 |
| Septic shocka | 5 (9.6) | 5 (23.8) | 0 | 0.008 |
| Acute kidney injuryb | 4 (7.7) | 4 (19.0) | 0 | 0.022 |
| AMIc | 1 (1.9) | 1 (4.8) | 0 | 0.404 |
| days form onset to severe event | 11.00 (8.50-16.50) | 11.00 (8.50-16.50) | NA. | NA. |
| Death | 8 (15.4) | 8 (38.1) | 0 | <0.001 |
ECMO, extracorporeal membrane oxygenation; α-GI, α-Glucosidase inhibitor; DPP4, dipeptidyl peptidase-4; ARDS, acute respiratory distress syndrome; AMI, acute myocardial infarction; NA, not available.
a
Three patients had ARDS by co-incidence.
b
Two patients had ARDS by co-incidence.
c
One patient had ARDS by co-incidence.